2010 versus the 2000 consensus criteria in patients with normalised insulin‐like growth factor 1 after transsphenoidal surgery has high predictive values for long‐term recurrence‐free survival in acromegaly - Shen - 2021

Elevated insulin‐like growth factor‐1 in patients without clinical evidence of acromegaly - Careless - 2023 - Clinical Endocrinology - Wiley Online Library

Diffuse Hormonal Systems - Endotext - NCBI Bookshelf

Characteristics of Gut Microbiota in Patients with GH-Secreting Pituitary Adenoma

Personalized Medical Treatment of Patients With Acromegaly: A Review - ScienceDirect

The p300 Inhibitor A-485 Exerts Antitumor Activity in Growth Hormone Pituitary Adenoma. - Abstract - Europe PMC

IJMS, Free Full-Text

Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future in: Endocrine-Related Cancer Volume 23 Issue 12 (2016)

PDF) Interpreting growth hormone and IGF-I results using modern assays and reference ranges for the monitoring of treatment effectiveness in acromegaly

General Cardiovascular Risk Profile for Use in Primary Care

Chapters Archive - Page 11 of 44 - Endotext

PDF) Contemporary Management of Acromegaly: A Practical Approach

PDF) Treatment of Acromegaly by Rosiglitazone via up-regulating 15-PGDH in Both Pituitary Adenoma and Liver